Selective indications for the use of praziquantel in the treatment of brain cysticercosis.
AUTOR(ES)
Vasconcelos, D
RESUMO
The selective use of praziquantel for the treatment of brain cysticercosis in human beings is described, based upon the results of clinical tests conducted during a 2 year period. Forty patients with clinical diagnosis of cysticercosis, confirmed and documented by CT, were treated. They are divided into four groups, representative of the various forms of the disease. The results assessed by clinical evaluation and sequential CT, give a ten point criterion of the indications for praziquantel.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1031869Documentos Relacionados
- Granuloma cytokines in murine cysticercosis.
- Oral albendazole in the management of extraocular cysticercosis.
- Enzyme-linked immunosorbent assay for the diagnosis of cerebral cysticercosis.
- Evaluation of enzyme-linked immunoassay for serological diagnosis of cysticercosis.
- Immunoglobulin E and G4 antibodies in cysticercosis.
